Stay updated with breaking news from Smart Growth Operational Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the largest contract research organizations (CRO) in Europe, announced today completion of the construction of...
Even 300,000 PLN non-returnable grant for the development of economic activity in Poland Even 300,000 PLN a non-returnable grant to get start-ups under the “Acceleration Programs – Poland Prize”. The Polish Agency for Enterprise Development has just selected new entities that will work with the originators and awarding funds for the implementation of young, perspective projects. The initiative is aimed exclusively at foreign start-ups. The initiative is aimed at attracting interesting, innovative projects to the Vistula River, which from the initial phase, thanks to the aid from the pro...
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company” or “ WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National Center for Research and Development (“ NCRD”), for the development of Annamycin, the Company’s drug candidate used in the treatment of Acute Myeloid Leukemia (“ AML”). Annamycin is a “next generation” anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multid...
Share: WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the " Company" or " WPD") a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10 th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021. During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: "New approach to glioblastoma treatment addressing the critical unmet medical need", granted by National Research and Development Center (" NRDC") a...
Share this article HOUSTON, Feb. 18, 2021 /PRNewswire/ -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical...